List view / Grid view
By surveying gene expression, researchers have created a reference atlas for understanding the biology of inflammatory bowel disease and food allergies, among other conditions...
Researchers have used a modified version of the gene-editing technique CRISPR in search for gene activators...
Although anti-inflammatory treatments are quite effective at reducing symptoms in patients with Crohn's disease and ulcerative colitis, the mucosal lining of the intestine often remains ulcerated, and many patients still ultimately require surgery.
7 January 2016 | By Nicholas Jackson
Enterome announces collaboration with Johnson & Johnson Innovation focused on the discovery of novel targets and therapeutics for Crohn’s disease...
25 November 2015 | By Victoria White
The transaction, expected to complete next month, is aimed at strengthening ReproCELL’s pharmaceutical industry-targeted drug discovery services...
11 November 2015 | By Victoria White
Of the total investment, EUR 5 billion will go to preclinical R&D with EUR 1.5 billion thereof planned for collaborations with external partners...
10 November 2015 | By Victoria White
The collaborations aim to identify and validate potential new therapeutic targets as well as identify biomarkers...
3 September 2015 | By Victoria White
The deals market for antisense RNAi therapeutics witnessed a record year in 2014, with a total value of almost $5.6 billion across 59 transactions...
15 June 2015 | By Victoria White
Researchers have found that modulation of B lymphocyte function may be a means of regulating T lymphocyte function to treat immune-mediated disorders...
18 March 2015 | By Victoria White
TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
26 February 2015 | By TxCell
TxCell invited to speak at largest US meeting for investors in emerging growth companies...
26 February 2015 | By MSD
Expansion in treatment options for moderately to severely active disease allows patients access to REMICADE® (infliximab), SIMPONI® (golimumab) and Humira® (adalimumab)...
25 February 2015 | By Mundipharma
Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets...
23 February 2015 | By Celltrion Healthcare
Cost savings could help improve patient access to life-changing treatment...
5 February 2015 | By TxCell
TxCell, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, reports its revenues as of December 31, 2014 and updates on forthcoming milestones...
